Irinotecan News and Research

RSS
Irinotecan hydrochloride is approved by the Food and Drug Administration (FDA) to be used with other drugs to treat colorectal cancer that has metastasized (spread to other parts of the body). It is also approved to treat metastatic colorectal cancer that has recurred (come back) or gotten worse after earlier chemotherapy. In addition to the uses that have been approved by the FDA, irinotecan hydrochloride is sometimes used to treat other types of cancer. Irinotecan hydrochloride is also being studied in the treatment of other types of cancer.
FDA grants approval for new biosimilar to treat multiple types of cancer

FDA grants approval for new biosimilar to treat multiple types of cancer

St. Jude creates world’s largest collection of pediatric solid tumor samples

St. Jude creates world’s largest collection of pediatric solid tumor samples

HHMI scientists expand access to new resource for studying pediatric cancers

HHMI scientists expand access to new resource for studying pediatric cancers

IQWiG finds colorectal cancer drug combination has added benefit only for some patients

IQWiG finds colorectal cancer drug combination has added benefit only for some patients

DNA-binding protein CHD1 could be potential biomarker for targeted prostate cancer treatment

DNA-binding protein CHD1 could be potential biomarker for targeted prostate cancer treatment

Study uncovers new drug-gene mutation combinations that can kill cancer cells

Study uncovers new drug-gene mutation combinations that can kill cancer cells

TAILOR study shows treatment with Erbitux plus FOLFOX improves survival in RAS wild-type mCRC patients

TAILOR study shows treatment with Erbitux plus FOLFOX improves survival in RAS wild-type mCRC patients

Novel anti-interleukin 1-alpha antibody shows promise in treating advanced colorectal cancer patients

Novel anti-interleukin 1-alpha antibody shows promise in treating advanced colorectal cancer patients

Bayer-new phase 3 liver cancer data

Bayer-new phase 3 liver cancer data

Study shows safety of experimental drug guadecitabine in colorectal cancer patients

Study shows safety of experimental drug guadecitabine in colorectal cancer patients

Celator provides update on Phase 3 clinical trial of VYXEOS in patients with untreated high-risk AML

Celator provides update on Phase 3 clinical trial of VYXEOS in patients with untreated high-risk AML

Novel test could help get best treatment for advanced bowel cancer patients

Novel test could help get best treatment for advanced bowel cancer patients

VARI-SU2C Epigenetics Dream Team supports new clinical trial that targets metastatic colorectal cancer

VARI-SU2C Epigenetics Dream Team supports new clinical trial that targets metastatic colorectal cancer

First patients treated in Phase 1b trial of pembrolizumab with REOLYSIN in advanced pancreatic adenocarcinoma

First patients treated in Phase 1b trial of pembrolizumab with REOLYSIN in advanced pancreatic adenocarcinoma

CTCA at Western announces launch of Phase II NivoPlus clinical trial

CTCA at Western announces launch of Phase II NivoPlus clinical trial

Novel anticancer agent appears to have greater potency, longer efficacy than irinotecan and topotecan

Novel anticancer agent appears to have greater potency, longer efficacy than irinotecan and topotecan

Advanced pancreatic cancer patients now have access to new FDA-approved drug, Onivyde

Advanced pancreatic cancer patients now have access to new FDA-approved drug, Onivyde

Novel therapy gets FDA approval for patients with metastatic pancreatic adenocarcinoma

Novel therapy gets FDA approval for patients with metastatic pancreatic adenocarcinoma

New combination treatment approved by FDA for metastatic pancreatic cancer

New combination treatment approved by FDA for metastatic pancreatic cancer

FDA approves LONSURF for treatment of patients with metastatic colorectal cancer

FDA approves LONSURF for treatment of patients with metastatic colorectal cancer